Adamas Pharma rises after IPO raises $48 million

April 10, 2014

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

In morning trading, the stock added $1, or 6.3 percent, to $17.

Adamas Pharmaceuticals Inc. is developing drugs that treat central nervous system disorders such as Parkinson's and Alzheimer's disease. It worked with Forest Laboratories Inc. on Namenda XR, an extended-release version of a Forest drug that treats Alzheimer's. The two companies have been studying a that combines Namenda XR with donepezil, or Aricept. Forest filed for approval of that pill in March.

Shares of the Emeryville, Calif., company are trading under the symbol "ADMS" on the Nasdaq Global Market.

Explore further: KaloBios Pharma edges higher following IPO

Related Stories

Recommended for you

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.